Physician profile
Daniel E Paul
NPI 1841283462
$1,444.64
in general payments reported to CMS, 2019-2025
23 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $32.06 · 2021: $155 · 2022: $109 · 2023: $484 · 2024: $291 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $312.39 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $207.07 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $149.80 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Daiichi Sankyo INC. | $121.53 | 2021-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $78.87 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.58 | 2019-2022 | |
| Novo Nordisk INC | $61.83 | 2023-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $45.57 | 2025 | Intracept |
| Abbott Laboratories | $44.66 | 2023 | Amplatzer Amulet |
| Astrazeneca Pharmaceuticals Lp | $42.49 | 2024 | Breztri |
| Masimo Corporation | $40.88 | 2023-2025 | Set and Rainbow Set, Patient Safetynet System |
| Novartis Pharmaceuticals Corporation | $40.26 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $32.16 | 2021-2024 | |
| Ani Pharmaceuticals, INC. | $28.82 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $27.05 | 2019-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26.53 | 2019 | |
| Eisai INC. | $22.95 | 2024 | |
| Medtronic, INC. | $18.88 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.85 | 2019 | |
| Edwards Lifesciences Corporation | $15.62 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Davol INC. | $14.06 | 2024 | Arista Ah Flexitip |
| Alnylam Pharmaceuticals INC. | $13.08 | 2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.